
**Supplementary information to:
When will clinical trials finally reflect diversity?**

To accompany a Comment published in Nature 557, 157–159 (2018)
<https://www.nature.com/articles/d41586-018-05049-5>

by Todd C. Knepper & Howard L. McLeod

Supplementary Tables

Supplementary Table 1. List of drugs included in analysis

| Trade Name | Non-Proprietary name | Year Approved | Area | Chemical Type |
|------------------|-------------------------------|---------------|------|--------------------------------|
| Gabitril | tiagabine | 1997 | CNS | 1 - New molecular entity (NME) |
| Mirapex | pramipexol | 1997 | CNS | 1 - New molecular entity (NME) |
| Requip | ropinorole | 1997 | CNS | 1 - New molecular entity (NME) |
| Seroquel | quetiapine | 1997 | CNS | 1 - New molecular entity (NME) |
| Zomig | zolmitriptan | 1997 | CNS | 1 - New molecular entity (NME) |
| Apokyn | apomorphine | 2004 | CNS | 1 - New molecular entity (NME) |
| Cymbalta | duloxetine | 2004 | CNS | 1 - New molecular entity (NME) |
| Lunesta | eszopiclone | 2004 | CNS | 1 - New molecular entity (NME) |
| Lyrica | pregabalin | 2004 | CNS | 1 - New molecular entity (NME) |
| Prialt | ziconotide | 2004 | CNS | 1 - New molecular entity (NME) |
| Tysabri | natalizumab | 2004 | CNS | BLA |
| Fanapt | iloperidone | 2009 | CNS | 1 - New molecular entity (NME) |
| Saphris | asenapine | 2009 | CNS | 1 - New molecular entity (NME) |
| Savella | milnacipran | 2009 | CNS | 1 - New molecular entity (NME) |
| Amyvid | florbetapir F 18 | 2012 | CNS | 1 - New molecular entity (NME) |
| Aubagio | teriflunomide | 2012 | CNS | 1 - New molecular entity (NME) |
| Fycompa | perampanel | 2012 | CNS | 1 - New molecular entity (NME) |
| Belsomra | suvarxant | 2014 | CNS | 1 - New molecular entity (NME) |
| Hetlioz | tasimelteon | 2014 | CNS | 1 - New molecular entity (NME) |
| Movantik | naloxegol | 2014 | CNS | 1 - New molecular entity (NME) |
| Northera | droxidopa | 2014 | CNS | 1 - New molecular entity (NME) |
| Plegridy | peginterferon beta-1a | 2014 | CNS | BLA |
| Avalide + Avapro | irbesartan + HCTZ | 1997 | CV | 1 - New molecular entity (NME) |
| Baycol | cerivastatin | 1997 | CV | 1 - New molecular entity (NME) |
| Corlopam | fenoldopam | 1997 | CV | 1 - New molecular entity (NME) |
| Genesa | arbutamine | 1997 | CV | 1 - New molecular entity (NME) |
| Plavix | clopidogrel | 1997 | CV | 1 - New molecular entity (NME) |
| Teveten | eprosartan | 1997 | CV | 1 - New molecular entity (NME) |
| Caduet | amlodipine + atorvastatin | 2004 | CV | 4 - New combination |
| Lovaza | omega-3-acid ethyl esters | 2004 | CV | 1 - New molecular entity (NME) |
| Ventavis | iloprost | 2004 | CV | 1 - New molecular entity (NME) |
| Vytorin | simvastatin + ezetamibe | 2004 | CV | 4 - New combination |
| Atryn | recombinant antithrombin | 2009 | CV | BLA |
| Effient | prasugrel | 2009 | CV | 1 - New molecular entity (NME) |
| Exforge HCT | amlodipine + valsartan + HCTZ | 2009 | CV | 4 - New combination |
| Livalo | pitavastatin | 2009 | CV | 1 - New molecular entity (NME) |

| | | | | |
|-----------|--------------------------|------|-----|--------------------------------|
| Multaq | dronedarone | 2009 | CV | 1 - New molecular entity (NME) |
| Twynsta | telmisartan + amlodipine | 2009 | CV | 4 - New combination |
| Valturna | aliskiren + valsartan | 2009 | CV | 4 - New combination |
| Eliquis | apixaban | 2012 | CV | 1 - New molecular entity (NME) |
| Juxtapid | lomitapide | 2012 | CV | 1 - New molecular entity (NME) |
| Vascepa | icosapent ethyl | 2012 | CV | 1 - New molecular entity (NME) |
| Zontivity | vorapaxar | 2014 | CV | 1 - New molecular entity (NME) |
| Anzemet | dolasetron | 1997 | ONC | 1 - New molecular entity (NME) |
| Fareston | toremifene | 1997 | ONC | 1 - New molecular entity (NME) |
| Femara | letrozole | 1997 | ONC | 1 - New molecular entity (NME) |
| Neumega | oprelvekin | 1997 | ONC | BLA |
| Quadramet | samarium-153-Lexidronam | 1997 | ONC | 1 - New molecular entity (NME) |
| Rituxan | rituximab | 1997 | ONC | BLA |
| Alimta | pemetrexed | 2004 | ONC | 1 - New molecular entity (NME) |
| Avastin | bevacizumab | 2004 | ONC | BLA |
| Clolar | clofarabine | 2004 | ONC | 1 - New molecular entity (NME) |
| Erbitux | cetuximab | 2004 | ONC | BLA |
| Kepivance | palifermin | 2004 | ONC | BLA |
| Tarceva | erlotinib | 2004 | ONC | 1 - New molecular entity (NME) |
| Vidaza | azacitidine | 2004 | ONC | 1 - New molecular entity (NME) |
| Afinitor | everolimus | 2009 | ONC | 1 - New molecular entity (NME) |
| Arzerra | ofatumumab | 2009 | ONC | BLA |
| Folotyn | pralatrexate | 2009 | ONC | 1 - New molecular entity (NME) |
| Istodax | romidepsin | 2009 | ONC | 1 - New molecular entity (NME) |
| Votrient | pazopanib | 2009 | ONC | 1 - New molecular entity (NME) |
| Bosulif | bosutinib | 2012 | ONC | 1 - New molecular entity (NME) |
| Cometriq | cabozantinib | 2012 | ONC | 1 - New molecular entity (NME) |
| Erivedge | vismodegib | 2012 | ONC | 1 - New molecular entity (NME) |
| Iclusig | ponatinib | 2012 | ONC | 1 - New molecular entity (NME) |
| Inlyta | axitinib | 2012 | ONC | 1 - New molecular entity (NME) |
| Kyprolis | carfilzomib | 2012 | ONC | 1 - New molecular entity (NME) |
| Perjeta | pertuzumab | 2012 | ONC | BLA |
| Stivarga | regorafenib | 2012 | ONC | 1 - New molecular entity (NME) |
| Synribo | omacetaxine | 2012 | ONC | 1 - New molecular entity (NME) |
| Granix | TBO-Filgastim | 2012 | ONC | BLA |
| Xtandi | enzalutamide | 2012 | ONC | 1 - New molecular entity (NME) |
| Zalrap | ziv-aflibercept | 2012 | ONC | BLA |
| Beleodaq | belinostat | 2014 | ONC | 1 - New molecular entity (NME) |
| Blinacyto | blinatumomab | 2014 | ONC | BLA |
| Cyramza | ramucirumab | 2014 | ONC | BLA |
| Keytruda | pembrolizumab | 2014 | ONC | BLA |

| | | | | |
|----------|------------|------|-----|--------------------------------|
| Lynparza | olaparib | 2014 | ONC | 1 - New molecular entity (NME) |
| Opdivo | nivolumab | 2014 | ONC | BLA |
| Zydelig | idelalisib | 2014 | ONC | 1 - New molecular entity (NME) |
| Zykadia | ceritinib | 2014 | ONC | 1 - New molecular entity (NME) |